



SERUM LEVEL OF IL 22 IN PSORIATIC PATIENTS AND ITS RELATION TO DISEASE SEVERITY

Thesis

Submitted for Partial Fulfillment of Master Degree
In Dermatology, Venereology and Andrology

By

Noura Mohamed Mohamed Ahmed Shakran
(M.B.,B.Ch.)

Supervised by

Prof. Saleh Mohamed Hassan El Shiemy

Professor of Dermatology, Venereology and Andrology
Faculty of Medicine - Ain Shams University

Dr. Azza Esmat Mostafa

Lecturer of Dermatology, Venereology and Andrology
Faculty of Medicine - Ain shams University

Faculty of Medicine
Ain Shams University
2017

Acknowledgement

First of all, all praises and thanks to Allah, for making me able to complete this work,

I want to thank my parents & my family who gave me all aid and support.

I am sincerely grateful for the careful supervision, and hospitality of Prof. Saleh Mohamed Hassun El Shiemy, Professor of Dermatology, Venereology and Andrology. He provided me a lot of time and facilities to make this work possible.

This work would not have come to light without the support, kind supervision, and continuous direction of Dr. Azza Esmaf Mostafa, Lecturer of Dermatology, Venereology and Andrology. She provided me a powerful support and excellent guidance to make this work possible.

I would like also to extend my thanks Dr. Sehum Gouda Amin, lecturer of clinical pathology. Benha University, for her great assistance, sincere guidance and reliable advice throughout this work. She has been generous with time and effort in this work.

In short, I offer my deepest gratitude and thanks to my professors and colleagues.

Noura Mohamed

List of Contents

■ List of Abbreviations	I
■ List of Tables	IV
■ List of Figures	V
■ Introduction.....	1
■ Aim of the Work.....	3
■ Review of Literature	4
Chapter (1): Psoriasis.....	4
Chapter (2): Interleukin-22	42
■ Subjects and Methods	70
■ Results	80
■ Discussion.....	89
■ Summary	93
■ Conclusion.....	95
■ Recommendations	96
■ References	97
■ Arabic Summary	

List of Abbreviations

AMP	Anti-Microbial Peptides Antigen
APCs	Presenting Cells . Blood Brain Barrier .
BBB	Body Surface Area .
Ca²⁺	Calcium
CALML5	Calmodulin Like 5
CCR	Chemokine Receptor
CD	Cluster of differentiation
CIA	Collagen Induced Arthritis
CLA	Cutaneous Lymphocyte-associated Antigen
CNS	Central Nervous System
CNVs	Copy Number Variations
CRF2	Cytokine Receptor Family class 2
CXCL	Chemokine Ligand
DCs	Dendritic Cells
DLQI	Dermatology Life Quality Index
DNA	Deoxy Ribonucleic Acid Desmocollin 1
EAE	Experimental Autoimmune Encephalomyelitis
FGF	Epidermal Growth Factor
ELISA	Enzyme Linked Immunosorbent Assay
FDA	Food and Drug Administration
FLG	Profilaggrin
HBD	Human Beta Defensins
HLA	Human leukocyte antigen I
IBD	Inflammatory Bowel Disease
IFN	Interferon
IL-10-TF	Interleukin -10-related T cell derived inducible Factor
IL	Interleukin
IL-10R2	Interleukin-10 Receptor 2
IL-10RB	Interleukin-10 Receptor 2 encoding gene
IL-20R1	Interleukin -20 Receptor 1
IL-20R2	Interleukin -20 Receptor 2

IL-22BP: Interleukin -22 binding protein
IL-22R1.....: Interleukin -22 Receptor 1
IL-22RA1.....: Interleukin -22 Receptor 1-encoding gene
JAK.....: Janus Kinase
KCs: Kcratinocytes
KDa.....: Kilodalton
KDAP.....: Keratinocyte Differentiation-Associated Protein
KLK7: Kallikrein-7
KRT: Keratin gene
LCs.....: Langerhans cells
LST: Least Significant Difference
mDCs: myeloid Dendritic cells
ml.....: Milliliter
MMP.....: Matrix Metalloproteinase
mRNA.....: Messenger ribonucleic acid
MS.....: Multiple sclerosis
NB-UVB.....: Narrow Band UVB
NF- κ B: Nuclear Factor Kappa B
ng/L: Nanograms per litre
NKT: Natural Killer T- cells
PAP1: Pancreatitis-Associated Protein 1
PAI-1.....: Plasminogen activator inhibitor 1
PASI.....: Psoriasis Area and Severity Index
pDCs: Plasmacytoid Dendritic cells
PIIINP.....: Plasma Procollagen Type III Aminopcptide
PsA.....: Psoriatic arthritis
PSORS: Psoriasis Susceptibility Locus
PUVA.....: Psoralen plus Ultraviolet A
RA: Rheumatoid Arthritis
RHE: Reconstituted Human Epidermis
RT-PCR.....: Real Time Polymerase Chain Reaction
S100A7.....: Psoriasin
S100A8.....: Calgranulin A

S100A9.....: Calgranulin B
SD.....: Standard Deviation
SNPs.....: Single Nucleotide Polymorphisms
STAT.....: Signal transducers and activator of transcription
TGF.....: Transforming Growth Factor
Th.....: T helper cells
TIMP-1: Tissue-Inhibitor of Metalloprotease-1
TLR: Toll Like Receptor
TNF- α : Tumor necrosis factor alpha
T-reg: Regulatory T cells
UV: Ultraviolet
VEGF: Vascular Endothelial Growth Factor

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
Table (1):	The “Dermatology Life Quality Index“(DLQI) to evaluate the impact on quality of life by a skin disease.....	..33
Table (2):	Ustekinumab and anti TNF-ct approved by the FDA for psoriasis.....	..41
Table (3):	Description of personal data among cases and controls	..80
Table (4):	Description of medical data among cases.....	..81
Table (5):	Description of disease characteristics among cases.....	..82
Table (6):	Comparison between cases and controls as regard IL-22	..83
Table (7):	Level of IL-22 in relation to disease severity	..84
Table (8):	Sensitivity and specificity of IL-22 as measured bv cutoff point	..85
Table (9):	Correlations between different variables and IL-22 among cases.....	..86
Table (10):	Relations between different variables and IL-22 among cases.....	..88

List of Figures

Fig. (1):	Clinical types of psoriasis	9
Fig. (2):	Psoriasis Area and Severity Index	32
Fig. (3):	IL-10 family members with known crystal structures.....	44
Fig (4)	IL-22 and IL-10 receptors evolved to utilize shared subunits	48
Fig. (5):	Intracellular signaling pathways of IL-22.....	51
Fig. (6):	Pro inflammatory and protective properties of IL-22	54
Fig. (7):	Model of immune interactions in the psoriatic lesion.....	58
Fig. (8):	Role of the IL-22-IL-22R1 system in psoriasis.....	60
Fig. (9):	IL-22 induces many histological features of psoriasis in the epidermis	66
Fig. (10):	Division of the body in PASI score	72
Fig. (11):	Online PASI calculator	73
Fig. (12):	Psoriasis severity among cases	82
Fig. (13):	Comparison between cases and controls as regard IL-22 level.....	83
Fig. (14):	Distribution of IL-22 level according to disease severity.....	84

Fig. (15):	ROC curve using IL-22 level to differentiate between cases and controls.....	85
Fig. (16):	Correlation between IL-22 level and age	87
Fig. (17):	Correlation between IL-22 level and PASI.....	87

Abstract

Objectives the aim of this study was to detect a relation between serum levels of interleukin – 22 (IL -22) in patients with psoriasis and also to detect a relation of IL-22 with psoriasis area and severity index (PASI). **Background** IL-22 is highly expressed in several different chronic inflammatory conditions, including psoriasis, multiple sclerosis and rheumatoid arthritis. The best studied function for IL-22 is within the skin as it has an inflammatory role during skin inflammation. **Subjects and methods** the study was conducted on 40 patients with psoriasis and 40 age-matched and sex-matched healthy individuals. All patients were subjected to history taking and complete medical examination serum level of IL-22 were measured by enzyme-linked immunosorbent assay technique. Serum levels of IL-22 were statistically analyzed in relation to PASI. **Result** the serum levels of IL-22 were elevated in patients with psoriasis compared with healthy people ($p < 0.023$). the serum IL-22 was significantly higher in patients with severe psoriasis as compared with those with mild and moderate psoriasis. There was no statistically signification difference between the serum levels of IL-22 and disease duration. **Conclusion** the significant elevation in the serum level of IL-22 in patients with psoriasis when compared with that of healthy controls and the signification elevation in the serum levels of IL-22 playing a fundamental role in pathogenesis of psoriasis.

Keyword: Interleukin – 22 Psoriasis Psoriasis area and severity index

INTRODUCTION

Psoriasis is one of the most common immune mediated chronic inflammatory skin diseases affecting about 2% of the worldwide population. The etiology and pathogenic mechanisms of psoriasis are still unclear. However, substantial clinical and basic studies indicate that the cellular innate and adaptive immune responses, especially the activation of T cells and release of cytokines by T cells, play critical roles in the pathogenesis of psoriasis (*Nestle et al., 2009*).

Accumulating evidence suggests that a new subset of T cells, T helper 17 (Th17), may play an important role in the pathology of psoriasis and other immune-mediated inflammatory diseases (*Pan et al., 2013*).

Interleukin-22 (IL-22) is a cytokine produced by several different cellular sources such as Th17 (*Liang et al., 2006*) and Th22 cells (*Trifari et al., 2009*), and it has been implicated in many chronic autoimmune and inflammatory diseases like systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis (*Pan et al., 2012*).

It has been showed that IL-22 could inhibit keratinocyte terminal differentiation and could induce

psoriasis-like epidermis alterations (*Wolk et al., 2009*). Additionally, IL-22 mRNA was found significantly elevated in the psoriatic skin lesions (*Liu et al., 2007*).

In addition, IL-22 can synergize with the other pro-inflammatory cytokines to induce many of the pathogenic phenotypes from keratinocytes and to exacerbate disease progression (*Ouyang, 2010*). Due to its crucial roles in inflammation and proliferation cascade, IL-22 may have promise as a potential therapeutic target for psoriasis.

All these findings suggest that IL-22 may be implicated in the pathogenesis of psoriasis. Few studies have evaluated the relation between IL-22 level in psoriatic patients and the severity of the disease. We presume that such relation worth further studies.

AIM OF THE WORK

The aim of this thesis was:

- To evaluate serum level of IL-22 in patients with psoriasis vulgaris in relation to age and sex matched healthy controls
- To correlate serum level of IL-22 in patients with psoriasis with the disease severity according to PASI.

CHAPTER (1): PSORIASIS

Definition:

Psoriasis is a common, chronic, inflammatory skin disease that results from a polygenic predisposition combined with triggering factors, e.g. trauma, infections or medications (*Roberson and Bowcock, 2010*).

Epidemiology:

Approximately psoriasis affects 2-3% of population worldwide, with prevalence varying according to race and geographic location (*Tonel and Conrad, 2009*). The occurrence of psoriasis is more frequent in countries more distant from the equator (*Parisi et al., 2013*). Psoriasis is extremely rare to absent in certain ethnic groups, such as Africans, African-Americans, Japanese, Alaskans, Australians, and Norwegians (*Basko-Plluska and Petronic-Rosic, 2012*).

Men and women are equally affected. All age groups are affected with a peak onset during the second and third decades of life (early onset psoriasis). A second peak of onset occurs during the fifth and sixth decades of life (late onset psoriasis). Psoriasis patients have a natural history of

outbreaks followed by temporary remissions (*Griffiths and Barker, 2007*).

Clinical Picture:

The important clinical hallmarks are: erythema, thickening and scaling. The plaque type of psoriasis is the most common type (*Nickoloff and Nestle, 2004*).

The typical history includes itching, skin redness and scaling. Patients may report that their disease worsens in the winter and improves in the summer (*Lui and Mamelak, 2009*).

The plaques are irregular or oval and most often located on the scalp, trunk, and limbs, with a predilection for extensor surfaces such as the elbows and knees. Smaller plaques may coalesce into larger lesions, especially on the legs and sacral regions. Fissuring within plaques can occur when lesions are present over joint lines or on the palms and soles. Psoriatic plaques tend to be symmetrically distributed over the body. Lesions typically have a high degree of uniformity with few morphologic differences between the two sides. Psoriatic lesions are sometimes surrounded by a pale blanching ring referred to as Woronoff's ring (*Lui and Mamelak, 2009*).

If the characteristic silvery scales are removed via